Aker BioMarine reported second-quarter revenue rose 5% versus the prior year, reaching $57.90 million, the Norway-based supplier said on Friday. The rise was driven primarily by its Human Health Ingredients segment, which benefited from increased krill oil volumes and a larger proportion of capsulated oil sales.
Despite the top-line increase, quarterly results fell short of some street benchmarks. The reported revenue was below a consensus estimate of $60 million from one analyst. Adjusted EBITDA declined 4% year-over-year to $12.90 million, coming in under a $14 million estimate from two analysts.
The Human Health Ingredients division recorded a 17% year-on-year revenue gain, the company said, attributing the improvement to solid krill oil volume growth and a shift toward more capsulated oil sales. However, that segment’s EBITDA margin narrowed slightly compared with the same period last year as Aker BioMarine increased investments in sales and marketing.
By contrast, the Consumer Health Products segment experienced headwinds. Sales were down at key U.S. retail chains and the segment is in the midst of marketing repositioning at its Epion brand, factors the company said weighed on results for that business.
Looking forward, Aker BioMarine expects the Human Health Ingredients business to continue producing year-over-year growth and to deliver improved profitability. Management said it anticipates the Consumer Health Products segment will return to modest growth.
Separately, the company confirmed it is exploring strategic alternatives for the Human Health Ingredients unit and aims to close a transaction in 2026 if a suitable path is identified. The announcement frames the unit as a potential candidate for a standalone strategic move while the company works to balance near-term margin pressures with growth investments.
Takeaway: The quarter shows contrasting dynamics across the company’s businesses - robust krill oil demand boosting the ingredient arm, offset by margin pressure from sales and marketing spend and softer retail performance at the consumer-facing unit. Management’s plan to pursue strategic options for the Human Health Ingredients unit adds a defined timeline, with a target to complete a transaction in 2026.